Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Stock Information for Oncternal Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.